Çubukçu, ErdemÖlmez, Ömer FatihKanat, ÖzkanKabul, SelvaCanhoroz, MustafaAvcı, NilüferHartavi, MustafaDeligönül, AdemÇubukçu, SinemManavoğlu, Osman2024-11-212024-11-212014-01-011428-2526https://doi.org/10.5114/wo.2014.40454https://www.termedia.pl/Lack-of-prognostic-significance-of-adiponectin-immunohistochemical-expression-in-patients-with-triple-negative-breast-cancer,3,22210,0,1.htmlhttps://hdl.handle.net/11452/48286Introduction: Triple-negative breast cancers (TNBCs) -which lack the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2)-have no established markers that can be used for prognostic stratification. As adiponectin has been previously implicated in a more aggressive phenotype of primary breast cancer, we explored the relation between adiponectin immunohistochemical expression and prognosis in TNBCs.Material and methods: Immunohistochemical staining for adiponectin was performed in 38 TNBC patients. Disease-free survival (DFS) and overall survival (OS) served as the main outcome measures.Results: Of the 38 TNBC patients, 18 (47%) had negative and 20 (53%) positive adiponectin immunohistochemical expression. We did not find any significant association between adipo-nectin immunohistochemical expression and the baseline characteristics. In addition, there were no associations between adiponectin immunohistochemical expression and prognosis.Conclusions: Although our results suggest that adiponectin immunohistochemical expression is not of prognostic significance in TNBCs, further studies are warranted to determine the role of this adipokine in breast cancer biology.eninfo:eu-repo/semantics/openAccessTriple-negative breast cancerAdiponectinImmunohistochemistryPrognosisOncologyArticle000422070400006343818110.5114/wo.2014.40454